Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

FOREX-U.S. dollar skids from four-week high; euro gains

Wed, 9th Sep 2020 20:17

* Euro rises after Bloomberg report on ECB forecasts
* Sterling rises after EU says will not suspend Brexit talks
* BoC keeps rates steady; Canadian dollar up
* U.S. dollar to be well-supported until year-end -analyst
* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

(Adds new comment, updates prices)
By Gertrude Chavez-Dreyfuss
NEW YORK, Sept 9 (Reuters) - The U.S. dollar slid from a four-week high on Wednesday, led by losses
against the euro after a news report said European Central Bank officials have become more confident in
their outlook for the region's recovery.
The safe-haven greenback was also pressured by improving risk sentiment as U.S. stocks rebounded from
a sharp sell-off and as higher crude oil prices prompted gains in commodity currencies.
Some analysts, however, expect the dollar to hold recent gains after a steep fall the last few months.
Since the beginning of September, the dollar has risen 2% against a currency basket.
Citing euro area officials, Bloomberg News reported on Wednesday that the ECB's upcoming projections
for output and inflation will show only slight changes to the June outlook, with gross domestic product
for this year to be revised higher.
The report, which came ahead of Thursday's ECB monetary policy meeting, spurred euro buying.
"It seems like there is still strong optimism about a euro zone recovery," said Edward Moya, senior
market analyst at OANDA in New York. "It's going to need more support, but things are not as bad as
initially believed."
In afternoon trading, the euro rose 0.3% against the dollar to $1.1805, which pushed the
dollar index down 0.3% at 93.265. Earlier on Wednesday, the index advanced to a four-week peak of 93.664.
That said, Scotiabank chief FX strategist Shaun Osborne believes the dollar will remain firmer
relative to the major currencies into the year-end, citing extreme bets against it in the speculative
market.
"We can see the dollar well-supported, primarily because positioning has been quite heavily skewed,
especially towards the euro," Osborne said.
"I don't think with this pullback in the euro, we have seen anywhere near tidying up those significant
positions."
He also said the dollar tends to rally ahead of a U.S. presidential election, at least since the
1980s.
Against other currencies, the dollar fell 0.5% to 0.9130 Swiss franc.
The dollar rose 0.2% against the yen to 106.20 yen. Earlier, the safe-haven yen gained after
news of a delay in the roll-out of a COVID vaccine.
AstraZeneca Plc said it paused global trials, including large late-stage trials, of its
experimental coronavirus vaccine due to an unexplained illness in a study participant.
Sterling, meanwhile, briefly rose back above $1.30 after an EU statement said it would not suspend
Brexit negotiations over the British government's new internal market bill. The pound was last up 0.1% at
$1.2992.
The pound earlier fell to a six-week low, as new legislation on Britain's post-Brexit plans stoked
fears that trade talks with the European Union would derail.
Commodity currencies, one of many barometers to gauge risk appetite, gained as crude prices rose and
stocks advanced.
The Australian and New Zealand dollars rose against the greenback, both gaining 0.8% to US$0.7272
and US$0.6669, respectively.
The Canadian dollar recovered against the U.S. currency, which fell 0.6% to C$1.3160, after
the Bank of Canada held interest rates steady at 0.25% on Wednesday.

========================================================
Currency bid prices at 3:01 PM (1901 GMT)
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar EUR= $1.1807 $1.1779 +0.24% +5.32% +1.1833 +1.1754
Dollar/Yen JPY= 106.2000 106.0100 +0.18% -2.43% +106.2700 +105.8000
Euro/Yen EURJPY= 125.40 124.83 +0.46% +2.83% +125.6400 +124.4500
Dollar/Swiss CHF= 0.9123 0.9173 -0.55% -5.73% +0.9190 +0.9124
Sterling/Dollar GBP= 1.2990 1.2987 +0.02% -2.03% +1.3023 +1.2886
Dollar/Canadian CAD= 1.3153 1.3232 -0.60% +1.29% +1.3259 +1.3148
Australian/Doll AUD= 0.7274 0.7214 +0.83% +3.62% +0.7287 +0.7193
ar
Euro/Swiss EURCHF= 1.0773 1.0804 -0.29% -0.73% +1.0817 +1.0775
Euro/Sterling EURGBP= 0.9087 0.9068 +0.21% +7.49% +0.9130 +0.9060
NZ NZD= 0.6670 0.6618 +0.79% -0.98% +0.6685 +0.6602
Dollar/Dollar
Dollar/Norway NOK= 9.0093 9.1243 -1.26% +2.63% +9.1840 +9.0099
Euro/Norway EURNOK= 10.6395 10.7498 -1.03% +8.15% +10.8001 +10.6376
Dollar/Sweden SEK= 8.7492 8.8312 -0.61% -6.38% +8.8554 +8.7506
Euro/Sweden EURSEK= 10.3328 10.3966 -0.61% -1.30% +10.4160 +10.3329

(Reporting by Gertrude Chavez-Dreyfuss; Editing by Andrea Ricci and Dan Grebler)

Related Shares

More News

UK to give under 40s alternative to AstraZeneca vaccine

(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.

7 May 21 09:49

All under-40s to be offered alternative to AstraZeneca vaccine

All under-40s to be offered alternative to AstraZeneca vaccine

7 May 21 08:49

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

7 May 21 08:32

AstraZeneca's Imfinzi demonstrates benefit in combination with antibody

(Sharecast News) - AstraZeneca reported on Friday that 'Imfinzi' and tremelimumab with chemotherapy demonstrated an overall survival benefit in the 'POSEIDON' trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.

7 May 21 07:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.